Sign in
Taking people in United StatesEarly phase 1

Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD

Key facts

Who runs it
Rush University Medical Center
Where
Chicago, United StatesSee the site
Trial code
Status
Recruiting
Phase
Early phase 1
People taking part
270 people, planned
Started
1 Apr 2026
Expected to end
31 Dec 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cognitive Processing Therapy
  • Stellate Ganglion Block
Record updated
2 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Are 18 years or older
  • Are fluent in English
  • Have experienced a Criterion A traumatic event during their lifetime
  • Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5
  • Have not previously received a Stellate Ganglion Block
  • Have a smartphone that they can use for the entire duration of the study
  • Are willing and able to receive 2 injections (SGB or placebo) 2 weeks apart at the Rush Pain Clinic
  • Are willing and able to participate in daily Cognitive Processing Therapy or Daily Monitoring over the course of one week
  • Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study

Who cannot take part

  • They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study
  • They have completed an evidence-based cognitive behavioral PTSD treatment (e.g., Cognitive Processing Therapy or Prolonged Exposure) in the past 3 months or are currently receiving an evidence-based PTSD treatment
  • They are currently on any blood-thinning medications or have a coagulopathy -They have any of the following conditions: a recent myocardial infarction, glaucoma, a pre- existing contralateral nerve palsy, severe emphysema, or a cardiac conduction blockade
  • They have an intellectual disability or significant cognitive impairment that would prevent them from engaging fully in treatment
  • They are allergic to any of the medications injected (i.e., ropivacaine, lidocaine, propofol)
  • They have an active infection
  • They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year
  • They have a visual or auditory impairment that would prevent them from fully participating in study activities
  • The traumatic event occurred in the past month
  • They are currently suicidal or homicidal (i.e., plan and intent)
  • They have unmanaged psychosis or mania
  • They are involved with current legal actions related to the traumatic event that is anticipated to be targeted during treatment
  • They have substance dependence that, in the judgment of the Principal Investigator, may require hospitalization if substances were discontinued
  • Subjects who, at the time of consent, appear to have extenuating life circumstances (e.g., unstable housing, no internet access, etc.) which, in the judgment of the Principal Investigator, could affect the ability to deliver the intervention with fidelity

Where in United States

  • Rush University Medical CenterChicago, United StatesContact: Sarah Pridgen, MATaking people

About the trial

What the trial wants to find out

The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain.

Read full original descriptionShow less

The proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.

The 3 groups in the trial

  • Active Stellate Ganglion Block + Cognitive Processing TherapyExisting treatment, for comparison

    Participants in this arm will receive two active Stellate Ganglion Block Injections, two weeks apart. After receiving the first injection, participants will complete 10 sessions of Cognitive Processing Therapy over the course of one week.

    Treatment: Cognitive Processing Therapy and Stellate Ganglion Block

  • Placebo Injection + Cognitive Processing TherapySham treatment, for comparison

    Participants in this arm will receive two placebo (saline) Injections, two weeks apart. After receiving the first injection, participants will complete 10 sessions of Cognitive Processing Therapy over the course of one week.

    Treatment: Cognitive Processing Therapy

  • Active Stellate Ganglion Block + Daily Symptom MonitoringPlacebo, for comparison

    Participants in this arm will receive two active Stellate Ganglion Block Injections, two weeks apart. After receiving the first injection, participants will complete 5 sessions of daily symptom monitoring with a member of study staff over the course of one week.

    Treatment: Stellate Ganglion Block

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD: A Randomized Controlled Trial
Record updated
2 June 2026